利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

742 条记录 (耗时 0.031 秒)

    Medical injection device packaging
    1.
    发明授权
    Medical injection device packaging 有权

    公开(公告)号：US11642451B2

    公开(公告)日：2023-05-09

    申请号：US15840150

    申请日：2017-12-13

    申请人： TEVA PHARMACEUTICAL INDUSTRIES Ltd.

    发明人： Mark Horlock

    IPC分类号： A61M5/00

    CPC分类号： A61M5/002 ,  A61M5/008 ,  A61M2209/06

    摘要： Packaging for an injection device, the packaging including a channel extending longitudinally to accommodate the injection device, the channel including a longitudinal wall adjoining a base wall; a handling recess extending laterally and formed through the longitudinal wall, a positioning rib extending longitudinally and protruding from the base wall into the channel for insertion into a positioning recess of the injection device, the positioning rib arranged offset laterally from the recess and extending in a longitudinal field defined by the handling recess.

    ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE
    7.
    发明申请
    ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE 审中-公开

    公开(公告)号：US20190030016A1

    公开(公告)日：2019-01-31

    申请号：US16150977

    申请日：2018-10-03

    申请人： Malle Schmidt ,  Malle Päri ,  Marit Laos ,  Ants Maasalu ,  Kalle Kaljuste

    发明人： Malle Schmidt ,  Malle Päri ,  Marit Laos ,  Ants Maasalu ,  Kalle Kaljuste

    IPC分类号： A61K31/451 ,  G01N30/88 ,  C07D211/52 ,  C07D211/42 ,  C07D211/24

    CPC分类号： A61K31/451 ,  C07D211/24 ,  C07D211/42 ,  C07D211/52 ,  G01N30/88 ,  G01N2030/8872

    摘要： This invention provides an isolated compound having the structure: or a salt thereof.The invention also provides for a process for preparing 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidin-4-ol, 1-(3,3-bis(3-(methylsulfonyl)phenyl)propyl)-4-(3-(methylsulfonyl) phenyl)piperidone, 1,4-bis((3-(1-propylpiperidin-4-yl)phenyl)sulfonyl)butane, (3R,4S)-4-(3-(methylsulfonyl)phenyl)-1-propylpiperidin-3-ol, 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidine 1-oxide, 1-(2-methylpentyl)-4-(3-(methylsulfonyl)phenyl)piperidine, 4-(3-(methylsulfinyl)phenyl)-1-propyl-1,2,3,6-tetrahydropyridine, and 4-(3-(methylsulfonyl)phenyl)-1-propyl-1,2,3,6-tetrahydropyridine.This invention also provides an impurity or a salt thereof for use, as a reference standard to detect trace amounts of the impurity in a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof. This invention further provides a process for producing a pridopidine drug product comprising obtaining a pridopidine drug substance and. mixing the pridopidine drug substance with suitable excipients so as to produce the pridopidine drug product. This invention also provides a process for producing a pridopidine drug product. This invention also provides a process of distributing a pridopidine drug product.

    COMBINATION OF LAQUINIMOD AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE
    8.
    发明申请
    COMBINATION OF LAQUINIMOD AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE 审中-公开

    公开(公告)号：US20180250285A1

    公开(公告)日：2018-09-06

    申请号：US15974112

    申请日：2018-05-08

    申请人： Michael HAYDEN

    发明人： Michael HAYDEN

    IPC分类号： A61K31/4704 ,  B65D81/32 ,  A61K31/451

    CPC分类号： A61K31/4704 ,  A61K31/451 ,  A61K2300/00 ,  B65D81/32

    摘要： This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease (HD), comprising administering to the patient laquinimod as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and pridopidine for treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention also provides laquinimod for use as an add-on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention further provides use of laquinimod and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder, e.g., HD.

    Treatment of Multiple Sclerosis With Combination of Laquinimod and Dimethyl Fumarate
    10.
    发明申请
    Treatment of Multiple Sclerosis With Combination of Laquinimod and Dimethyl Fumarate 审中-公开

    公开(公告)号：US20180050031A1

    公开(公告)日：2018-02-22

    申请号：US15803017

    申请日：2017-11-03

    申请人： Teva Pharmaceutical Industries, Ltd.

    发明人： Joel Flaxman Kaye

    IPC分类号： A61K31/4704 ,  A61K45/06 ,  A61K31/225 ,  A61K31/47

    CPC分类号： A61K31/4704 ,  A61K31/225 ,  A61K31/47 ,  A61K45/06 ,  A61K2300/00

    摘要： This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with DMF. This invention also provides a package comprising laquinimod and DMF for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with DMF in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides a pharmaceutical composition comprising laquinimod and DMF for use in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and DMF in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.